2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications.
Chatterjee
S
S
Gallen
I W
IW
Sandler
L
L
D001835:Body Weight; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000592:standards / Q000627:therapeutic use; D061268:Insulin Lispro; D011785:Quality Assurance, Health Care; D006113:United Kingdom
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro